To view this email as a web page, click here.
October 10, 2019
 
Ixekizumab Bests Adalimumab at 24 Weeks in Psoriatic Arthritic Skin, Joint Symptoms
Ixekizumab was superior to adalimumab at 24 weeks in a head-to-head trial evaluating both skin and joint symptoms in patients with psoriatic arthritis and inadequate response to csDMARDs, say researchers writing in Annals of the Rheumatic Diseases last month.
Read more
 
ASBMR Issues New Recommendations for Preventing Secondary Fractures
The American Society for Bone and Mineral Research has developed clinical recommendations for the prevention of secondary fractures for patients aged 65years and older after an initial hip or vertebral fracture.
Read more
 
Social Support May Help Joint Replacement Outcomes
Social support may be a prognostic factor for some joint-specific and general health outcomes after hip or knee replacement, say researchers writing in The Lancet Rheumatology this month.
Read more
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.